Pyrazofurin-resistant hepatoma cells deficient in adenosine kinase.
D000241:Adenosine / Q000494:pharmacology; D000248:Adenosine Kinase / Q000378:metabolism*; D000577:Amides; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000201:enzymology*; D009964:Orotidine-5'-Phosphate Decarboxylase / Q000378:metabolism; D010754:Phosphoribosyl Pyrophosphate / Q000378:metabolism; D010770:Phosphotransferases / Q000378:metabolism*; D011720:Pyrazoles; D012263:Ribonucleosides / Q000494:pharmacology*; D012265:Ribonucleotides / Q000032:analysis; D012266:Ribose
D000577:Amides; D000903:Antibiotics, Antineoplastic; D011720:Pyrazoles; D012263:Ribonucleosides; D012265:Ribonucleotides; C002997:pyrazofurin; D012266:Ribose; D010754:Phosphoribosyl Pyrophosphate; D010770:Phosphotransferases; D000248:Adenosine Kinase; D009964:Orotidine-5'-Phosphate Decarboxylase; D000241:Adenosine